• Mashup Score: 1

    During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Which factors help guide therapy choice for relapsed/refractory (R/R) diffuse large B-cell lymphoma?

    Tweet Tweets with this article
    • ⏰ Catch up with this! During #EHA2021, the Lymphoma Hub spoke with @gilles_salles, @sloan_kettering. We asked, Which factors help guide therapy choice for relapsed/refractory (R/R) diffuse large B-cell lymphoma? πŸ‘‰ https://t.co/Oqv4ZRKP8T πŸ‘ˆ #lymsm #lymphoma https://t.co/oeNZhzWRLK

  • Mashup Score: 0

    During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML?

    Tweet Tweets with this article
    • 🎧 Did you listen to this podcast! During the #EHA2021 Virtual Congress, @AML_Hub spoke with @nagler_EBMT, @StudyTAU. We asked, Should pre-transplant MRD be used to guide treatment in #AML? πŸ‘‰ https://t.co/Ko1hZvYSf7 πŸ‘ˆ #amlsm #leusm #leukemia https://t.co/gkMr7wHREQ

  • Mashup Score: 0

    During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?

    Tweet Tweets with this article
    • ⏰ Catch up with this! Listen to this #EHA2021 podcast! The #LymphomaHub spoke to @GOssenkoppele, @amsterdamumc. We asked, Should pre-transplant #MRD be used to guide treatment in #AML? 🎧 https://t.co/Mko77W17Nk 🎧 #AMLsm #leusm #leukemia https://t.co/pGf42gsK2w

  • Mashup Score: 0

    During the EHA2021 Virtual Congress, the AML Hub spoke with Olga Gavrilina, National Research Center for Hematology, Moscow, RU. We asked, How does COVID-19 affect outcomes in AML?

    Tweet Tweets with this article
    • πŸ“Ή Weekend Watch! During #EHA2021 The #AMLHub spoke with Olga Gavrilina, National Research Center for Hematology, Moscow. We asked, How does #COVID19 affect outcomes in #AML? πŸ‘‰ https://t.co/Ic7GeLzYmZ πŸ‘ˆ #AMLsm #leukemia #leusm

  • Mashup Score: 0

    During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, Which relapsed/refractory AML subgroups would benefit from enasidenib treatment?

    Tweet Tweets with this article
    • πŸ‘€ Have you seen this? During #EHA2021 the #AMLHub spoke with Courtney DiNardo, @MDAndersonNews. We asked, Which r/r #AML subgroups would benefit from enasidenib treatment? πŸ’Š πŸ‘‰ https://t.co/6PdnTDOfHS πŸ‘ˆ #leusm #amlsm

  • Mashup Score: 0

    During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory AML treatment with venetoclax and hypomethylating agents (HMAs)?

    Tweet Tweets with this article
    • ⏰ Catch up with this! During #EHA2021 The #AMLHub spoke with Courtney DiNardo, @MDAndersonNews. We asked, what is the real-world experience of r/r #AML treatment with venetoclax and hypomethylating agents (HMAs)❓ πŸ‘‰ https://t.co/bzcqFFZ74G πŸ‘ˆ #leusm #amlsm #leukemia